Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection
暂无分享,去创建一个
T. Sørlie | F. B. Sørensen | S. Myhre | J. Overgaard | J. Alsner | T. Tramm | G. Hennig | M. Kyndi
[1] B. S. Sørensen,et al. Optimal Reference Genes for Normalization of qRT-PCR Data from Archival Formalin-fixed, Paraffin-embedded Breast Tumors Controlling for Tumor Cell Content and Decay of mRNA , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[2] Andrew H. Beck,et al. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype , 2013, Breast Cancer Research.
[3] Simen Myhre,et al. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins , 2013, Molecular oncology.
[4] H. Mouridsen,et al. [Danish Breast Cancer Cooperative Group]. , 2012, Ugeskrift for laeger.
[5] R. Greil,et al. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.
[6] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Renoir,et al. Cracking the estrogen receptor's posttranslational code in breast tumors. , 2011, Endocrine reviews.
[8] Carsten Denkert,et al. Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue—A New Option for Predictive Biomarker Assessment in Breast Cancer , 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[9] N. Udvarhelyi,et al. Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they? , 2011, Pathology & Oncology Research.
[10] Hiltrud Brauch,et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. , 2010, Clinical chemistry.
[11] A. Frigessi,et al. In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome , 2010, PloS one.
[12] L. Pusztai,et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. , 2010, The oncologist.
[13] Rolf Jaggi,et al. Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue , 2010, BMC Cancer.
[14] M. J. van de Vijver,et al. Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.
[15] Uwe Rogel,et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.
[16] A. Tutt,et al. A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. , 2009, The Journal of molecular diagnostics : JMD.
[17] Krystyna Kiel,et al. Breast cancer. Clinical practice guidelines in oncology. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. B. Sørensen,et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Gelber,et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] F. B. Sørensen,et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. , 2008, Acta oncologica.
[22] I. Christensen,et al. Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications , 2008, Acta oncologica.
[23] Ian O Ellis,et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Cronin,et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue , 2007, Breast Cancer Research and Treatment.
[26] Lajos Pusztai,et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.
[27] S. Hilsenbeck,et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Paik,et al. Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer , 2005, Nature Clinical Practice Oncology.
[29] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[30] Mårten Fernö,et al. Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer Clinical Associations and Reasons for Discrepancies , 2003, Acta oncologica.
[31] P. Bendahl,et al. Estrogen and Progesterone Receptor Assay in Paraffin-Embedded Breast Cancer , 2003, Acta oncologica.
[32] H. Storm,et al. Validity and Representativity in the Danish Breast Cancer Cooperative Group , 2003, Acta oncologica.
[33] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Bentzen,et al. Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation. , 1988, European journal of cancer & clinical oncology.
[35] H. J. G. GUNDERSEN,et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[36] B. S. Sørensen,et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] Debjani Dutta,et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.